Eduard Holdener - PAREXEL International Independent Director

<div class='circular--portrait' style='background:#000000;color: white;font-size:3em;padding-top: 25px;;'>PRX</div>
Dr. Eduard E. Holdener, M.D., is Independent Director of Parexel International Corporationrationration. is a member of the Human Resources Committee. Since February 2008, Dr. Holdener has served as Chairman of the Board of Directors, and since December 2015 he has also served as Chief Executive Officer, of NovImmune S.A., a biotechnology company. From April 1986 to February 2008, Dr. Holdener worked for F. HoffmannLaRoche, Ltd., a pharmaceutical company. During his tenure at F. HoffmannLaRoche, he held a variety of positions, including Head of Global Pharmaceutical Development, Development Head for the Japanese division, Deputy Clinical Research Head, and several other management positions. Dr. Holdener currently serves on the boards of directors of NovImmune S.A., and HBM Healthcare.
Age: 71  Director Since 2008  Ph.D    
781 487-9900
Holdener currently serves on the boards of directors of NovImmune S.A., TiGenix NV, and HBM Healthcare. We believe Dr. Holdener?s experience of 24 years as an executive in the pharmaceutical and biotechnology industries is valuable to our Board and the Company.

Management Efficiency

The company has return on total asset (ROA) of 4.71 % which means that it generated profit of $4.71 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 15.1 % meaning that it created $15.1 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Fei WangOrigin Agritech Limited
Shlomo YanaiPerrigo Company Plc
Yuchun LeeVertex Pharmaceuticals Incorpor
Gregory NordenZoetis
Linda RhodesZoetis
Jacqualyn FousePerrigo Company Plc
Robert ScullyZoetis
Theodore SamuelstoPerrigo Company Plc
James KangOrigin Agritech Limited
Charles BakerRegeneron Pharmaceuticals
David AltshulerVertex Pharmaceuticals Incorpor
Bradley AlfordPerrigo Company Plc
Geoffrey ParkerPerrigo Company Plc
Donal OConnorPerrigo Company Plc
Willie ReedZoetis
Shikha SharmaDr Reddys Laboratories Ltd
Elaine UllianVertex Pharmaceuticals Incorpor
Louise ParentZoetis
Bruce SachsVertex Pharmaceuticals Incorpor
Min TangOrigin Agritech Limited
Yingqi XiaOrigin Agritech Limited

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Return On Equity15.10
Return On Asset4.71
Profit Margin4.09